Study S000870

Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02014259
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 71
Start: 2013-12-11
Primary completion: 2014-10-24
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: DRUG:semaglutide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2013-000682-36; OTHER:U1111-1139-4281

Registered primary outcomes

Area under the semaglutide plasma concentration time curve [From time 0 to 24 hours after the 10th dosing]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011209	Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Overgaard RV, Clinical pharmacokinetics	2021	Other trial	PMID 33969456 DOI	cites ClinicalTrials.gov:NCT02014259
R0017720	Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. Granhall C, Clinical pharmacokinetics	2018	Other trial	PMID 29623579 DOI	cites ClinicalTrials.gov:NCT02014259; registry reference RESULT:29623579